Compare STEX & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | STEX | RFL |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | 6 | N/A |
| Industry | | Real Estate |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.3M | 92.6M |
| IPO Year | N/A | 2017 |
| Metric | STEX | RFL |
|---|---|---|
| Price | $0.80 | $2.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 274.0K |
| Earning Date | 05-17-2026 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,044.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $0.70 | $1.12 |
| 52 Week High | $7.44 | $2.95 |
| Indicator | STEX | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 73.51 |
| Support Level | $0.70 | $1.22 |
| Resistance Level | $1.12 | N/A |
| Average True Range (ATR) | 0.10 | 0.32 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 21.74 | 81.75 |
Streamex Corp is a vertically integrated technology and infrastructure company. The Company is a technology company with two principal lines of business: (i) Tokenized Asset Finance, focused on digital asset and real-world asset tokenization via Streamex Exchange platform, and (ii) Biomedical Technology, focused on signal processing solutions in electrophysiology. The group provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. It is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.